Brandywine Global Investment Management LLC Makes New $33.80 Million Investment in Genmab A/S (NASDAQ:GMAB)

Brandywine Global Investment Management LLC acquired a new stake in Genmab A/S (NASDAQ:GMAB) in the fourth quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor acquired 1,619,764 shares of the company’s stock, valued at approximately $33,804,000. Brandywine Global Investment Management LLC owned approximately 0.24% of Genmab A/S as of its most recent filing with the SEC.

A number of other large investors have also recently bought and sold shares of GMAB. Charles Schwab Investment Management Inc. lifted its position in Genmab A/S by 94.1% during the 3rd quarter. Charles Schwab Investment Management Inc. now owns 26,104 shares of the company’s stock valued at $636,000 after purchasing an additional 12,654 shares during the period. AIMZ Investment Advisors LLC acquired a new stake in Genmab A/S in the 4th quarter valued at about $3,525,000. HighTower Advisors LLC bought a new position in shares of Genmab A/S in the third quarter valued at about $273,000. Verition Fund Management LLC bought a new stake in shares of Genmab A/S during the third quarter worth approximately $709,000. Finally, FMR LLC lifted its holdings in shares of Genmab A/S by 13.5% during the third quarter. FMR LLC now owns 278,194 shares of the company’s stock worth $6,782,000 after buying an additional 33,076 shares in the last quarter. 7.07% of the stock is currently owned by institutional investors.

Analysts Set New Price Targets

Several equities analysts have commented on the stock. Truist Financial decreased their target price on shares of Genmab A/S from $50.00 to $45.00 and set a “buy” rating on the stock in a report on Tuesday, March 11th. Leerink Partnrs upgraded Genmab A/S from a “hold” rating to a “strong-buy” rating in a report on Thursday, February 13th. HC Wainwright reissued a “buy” rating and issued a $50.00 price target on shares of Genmab A/S in a research report on Thursday, January 23rd. Leerink Partners raised Genmab A/S from a “market perform” rating to an “outperform” rating and set a $27.00 price target for the company in a research report on Thursday, February 13th. Finally, William Blair raised shares of Genmab A/S from a “market perform” rating to an “outperform” rating in a report on Tuesday, March 11th. Four analysts have rated the stock with a hold rating, eight have issued a buy rating and one has given a strong buy rating to the company’s stock. Based on data from MarketBeat.com, Genmab A/S presently has a consensus rating of “Moderate Buy” and a consensus price target of $41.33.

Genmab A/S Trading Down 1.2 %

GMAB opened at $19.90 on Friday. The firm has a market capitalization of $13.17 billion, a PE ratio of 11.44, a P/E/G ratio of 2.65 and a beta of 0.98. The firm has a 50 day moving average of $20.89 and a two-hundred day moving average of $21.88. Genmab A/S has a 12-month low of $18.64 and a 12-month high of $30.50.

Genmab A/S (NASDAQ:GMAB) last posted its earnings results on Wednesday, February 12th. The company reported $0.57 EPS for the quarter, beating analysts’ consensus estimates of $0.28 by $0.29. Genmab A/S had a return on equity of 16.78% and a net margin of 36.30%. As a group, analysts predict that Genmab A/S will post 1.45 EPS for the current fiscal year.

Genmab A/S Company Profile

Genmab A/S develops antibody therapeutics for the treatment of cancer and other diseases primarily in Denmark. The company markets DARZALEX, a human monoclonal antibody for the treatment of patients with multiple myeloma (MM); teprotumumab for the treatment of thyroid eye disease; and Amivantamab for advanced or metastatic gastric or esophageal cancer and NSCLC.